ArticleCureus2026
Adult Pneumococcal Vaccination in Latin America: The Next Step Beyond Pediatric Pneumococcal Conjugate Vaccine.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumococcal disease remains an important cause of morbidity and mortality among adults, particularly older individuals and those with chronic medical conditions. While pediatric pneumococcal conjugate vaccine (PCV) programs have substantially reduced vaccine-type disease and generated indirect protection through herd effects, a persistent burden of pneumococcal infection continues to affect adult populations in Latin America. Demographic ageing, the growing prevalence of chronic diseases, immunosenescence, and shifts in circulating pneumococcal serotypes contribute to sustaining this residual risk despite successful pediatric vaccination strategies. As epidemiologic patterns evolve, prevention policies must also adapt. Direct vaccination of adults offers an opportunity to reduce severe pneumococcal disease, hospitalisations, and preventable deaths among high-risk populations. Integrating adult pneumococcal vaccination into existing healthcare platforms, including primary care visits, chronic disease management programs, and hospital discharge protocols, represents a feasible pathway for implementation in the region. Strengthening adult immunisation strategies should therefore be viewed as the logical next step in pneumococcal disease prevention in Latin America, complementing the substantial progress achieved through pediatric vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.